|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 31/138 | (2006.01) |
| A61K 31/439 | (2006.01) | ||
| A61K 45/06 | (2006.01) | ||
| A61P 11/06 | (2006.01) | ||
| A61P 11/08 | (2006.01) |
| (11) | Number of the document | 3335707 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17206132.7 |
| Date of filing the European patent application | 2010-11-29 | |
| (97) | Date of publication of the European application | 2018-06-20 |
| (45) | Date of publication and mention of the grant of the patent | 2024-04-17 |
| (46) | Date of publication of the claims translation | 2024-06-10 |
| (30) | Number | Date | Country code |
| 0921075 | 2009-12-01 | GB |
| (72) |
BAKER, Darrell , GB
BRUCE, Mark , GB
CRATER, Glenn , US
NOGA, Brian , US
THOMAS, Marian , GB
WIRE, Patrick , US
|
| (73) |
Glaxo Group Limited ,
GSK Medicines Research Centre
Gunnels Wood Road, Stevenage SG1 2NY,
GB
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Muskarininio receptoriaus antagonisto ir beta-2 adrenoreceptoriaus agonisto deriniai |
| COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST |
| Payment date | Validity (years) | Amount | |
| 2024-10-22 | 15 | 289.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2025-06-13 |